Physician profile
Rose C Cofer
NPI 1225032022
$1,011.62
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $534 · 2021: $247 · 2022: $231.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $122.08 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $120.44 | 2019 | |
| Alexion Pharmaceuticals, INC. | $116.85 | 2019 | |
| Genzyme Corporation | $100.00 | 2019 | |
| Tris Pharma INC | $90.19 | 2021-2022 | |
| Glaxosmithkline, LLC. | $69.96 | 2019-2022 | |
| Sanofi Pasteur INC. | $66.41 | 2022 | |
| Rhythm Pharmaceuticals, INC. | $63.89 | 2022 | |
| Merck Sharp & Dohme LLC | $49.39 | 2021-2022 | |
| Cranial Technologies, INC | $47.86 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $42.06 | 2021 | |
| Corium, LLC | $34.78 | 2021-2022 | |
| Photocure INC | $23.88 | 2019 | |
| Kaleo, INC. | $23.46 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $23.10 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karl Storz Endoscopy-America | $17.27 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rose Cofer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.